The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation

Transplant Immunology

Volumn 24, Issue 4, 2011, Pages 224-232

  D'Aveni, Maud ^a,b   Aïssi Rothé, Lamia ^a,c   Venard, Véronique ^a   Salmon, Alexandra ^a   Falenga, Aude ^a   Decot, Véronique ^a,c   Virion, Jean Marc ^a   Wang, Yingying ^a,c   Clement, Laurence ^b   Latger Cannard, Véronique ^a   Tomowiak, Cécile ^b   Stoltz, Jean François ^a,c   Bordigoni, Pierre ^b   Bensoussan, Danièle ^a,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b HÔPITAL D ENFANTS   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Allogeneic hematopoietic; Epstein Barr virus; Specific immune reconstitution monitoring; Stem cell transplantation

Indexed keywords

CYCLOSPORIN; DNA; GAMMA INTERFERON; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; THYMOCYTE ANTIBODY; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS INFECTION; FEASIBILITY STUDY; FEMALE; GRAFT RECIPIENT; HEMOGLOBINOPATHY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION; IMMUNITY; IMMUNOCOMPROMISED PATIENT; LYMPHOCYTE COUNT; LYMPHOMA; MALE; MYELODYSPLASTIC SYNDROME; NEWBORN; NONHUMAN; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; RETROSPECTIVE STUDY; RISK FACTOR; T LYMPHOCYTE; VIRUS DETECTION; VIRUS LOAD;

EID: 79955426994     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2011.03.002     Document Type: Article

References (44)

1. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999, 94:2208-2216.
2. Hale G., Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998, 91:3079-3083.
3. Gerritsen E.J., Stam E.D., Hermans J., et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996, 18:377-382.
4. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
5. van Esser J.W., Niesters H.G., van der Holt B., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369.
6. Sirvent-Von Bueltzingsloewen A., Morand P., Buisson M., et al. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplant 2002, 29:21-28.
7. Kimura H., Morita M., Yabuta Y., et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999, 37:132-136.
8. Meerbach A., Wutzler P., Hafer R., Zintl F., Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008, 80:441-454.
9. Stevens S.J., Verschuuren E.A., Pronk I., et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001, 97:1165-1171.
10. Aalto S.M., Juvonen E., Tarkkanen J., et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007, 45:1305-1309.
11. Juvonen E., Aalto S., Tarkkanen J., Volin L., Hedman K., Ruutu T. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007, 92:819-825.
12. Wagner H.J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103:3979-3981.
13. Gartner B.C., Fischinger J., Schafer H., Einsele H., Roemer K., Muller-Lantzsch N. Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease. Recent Results Cancer Res 2002, 159:49-54.
14. Meij P., van Esser J.W., Niesters H.G., et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003, 101:4290-4297.
15. Lucas K.G., Small T.N., Heller G., Dupont B., O'Reilly R.J. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87:2594-2603.
16. Cavazzana-Calvo M., Bensoussan D., Jabado N., et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol 1998, 103:543-551.
17. Papadopoulos E.B., Ladanyi M., Emanuel D., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
18. Rooney C.M., Heslop H.E., Brenner M.K. EBV specific CTL: a model for immune therapy. Vox Sang 1998, 74:497-498. Suppl 2.
19. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
20. Gustafsson A., Levitsky V., Zou J.Z., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000, 95:807-814.
21. Kuehnle I., Huls M.H., Liu Z., et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000, 95:1502-1505.
22. Annels N.E., Kalpoe J.S., Bredius R.G., et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006, 42:1743-1748.
23. Clave E., Agbalika F., Bajzik V., et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004, 77:76-84.
24. Gottschalk S., Heslop H.E., Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005, 46:1-10.
25. Bordigoni P., Faure G., Bene M.C., et al. Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor (FTS). Lancet 1982, 2:293-297.
26. Aissi-Rothe L., Decot V., Venard V., et al. Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. J Immunother 2010, 33:414-424.
27. Comin-Anduix B., Gualberto A., Glaspy J.A., et al. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 2006, 12:107-116.
28. Tan L.C., Gudgeon N., Annels N.E., et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999, 162:1827-1835.
29. Kuzushima K., Hayashi N., Kudoh A., et al. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells. Blood 2003, 101:1460-1468.
30. Marshall N.A., Howe J.G., Formica R., et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96:2814-2821.
31. Koehne G., Smith K.M., Ferguson T.L., et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002, 99:1730-1740.
32. Kuzushima K., Hoshino Y., Fujii K., et al. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry. Blood 1999, 94:3094-3100.
33. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006, 108:1797-1808.
34. Amrolia P.J., Muccioli-Casadei G., Yvon E., et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003, 102:2292-2299.
35. Chakrabarti S., Milligan D.W., Pillay D., et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003, 102:839-842.
36. Chen X., Barfield R., Benaim E., et al. Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood 2005, 105:886-893.
37. Klenerman P., Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005, 6:873-879.
38. Nazaruk R.A., Rochford R., Hobbs M.V., Cannon M.J. Functional diversity of the CD8(+) T-cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 1998, 91:3875-3883.
39. Pantaleo G., Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006, 6:417-423.
40. Guerin V., Dalle J.H., Pedron B., et al. Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation. Bone Marrow Transplant 2010, 45:442-449.
41. Khourouj-Guerin V., Dalle J.H., Pedron B., et al. Quantitative and qualitative CD4 T-cell immune responses related to adenovirus DNAemia in hematopoietic-stem cell transplantation. Biol Blood Marrow Transplant 2010, 17(4):476-485.
42. Cwynarski K., Ainsworth J., Cobbold M., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97:1232-1240.
43. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25:587-617.
44. Masjosthusmann K., Ehlert K., Eing B.R., et al. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant 2009, 43:679-684.